Information Library
Presentations - Connect with investigators, regulators and physicians
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Incremental Cost of Otitis Media Among Children in the United States
June 25, 2009
Using a nationally representative data source, the study estimates the medical cost of treating otitis media among children in the US. The costs are estimated at $2 billion in 2005. -
Patient Registries: A Taxonomy for the Design, Development and Implementation
June 25, 2009
Recommendations from the ISPOR Patient Registry Classification, Strategy & Design Working Group, Team 2, for developing standard language for the characterization, classification, strategy, design, and execution of patient registries to generate data for outcomes research purposes. -
Medicare Part D’s Effect On Prescribing Volume
June 25, 2009
Poster presented during the ISPOR 14th Annual International Meeting 2009 (International Society for Pharmacoeconomics and Outcomes Research) titled “Medicare Part D’s Effect On Prescribing Volume: Average Monthly Utilization of Selected High Use Drugs In The Six Protected Classes, By Different Specialties.” -
Orphan Drugs in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009(International Society for Pharmacoeconomics and Outcomes Research) on “Orphan Drugs' Market Access in the U.S.” -
Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009 (International Society for Pharmacoeconomics and Outcomes Research) on “The Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.”
Page 1 of 1 (5 items)